Cardiac Amyloidosis is an uncommon yet serious medical condition characterized by the infiltration of amyloid proteins into the heart tissue, disrupting its normal function. These proteins, typically derived from misfolded antibodies or other precursor proteins, aggregate into insoluble fibrils, creating deposits within the heart. This accumulation adversely impacts the heart's structural integrity, hindering its ability to pump blood efficiently. The manifestation of symptoms such as fatigue, shortness of breath, and leg swelling underscores the severity of the condition. Due to its varied clinical presentation, diagnosing Cardiac Amyloidosis poses a significant challenge, emphasizing the importance of early detection for effective management. Treatment strategies may involve addressing the root cause, symptom management, and, in certain cases, resorting to organ transplantation. Ongoing research and advancements in diagnostic methods signify a collective effort to enhance outcomes and quality of life for individuals grappling with Cardiac Amyloidosis.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States